期刊
BIOMATERIALS ADVANCES
卷 133, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.msec.2021.112623
关键词
Doxorubicin (DOX); Cancer therapy; Nanostructures (Ns); Chemotherapy; Drug delivery systems (DDS); Drug encapsulation
资金
- State of Sao Paulo Research Foundation (FAPESP/Brazil) [2017/10789-1, 2018/10799-0, 2018/25994-2, 2019/08549-8, 2020/03727-2]
- National Council for Scientific and Technological Development (CNPq/Brazil) [123483/2020-4]
- Coordination for Higher Level Graduate Improvements (CAPES/Brazil) [001]
This review presents the use of various nanostructures for the encapsulation of doxorubicin (DOX) over the past 10 years. These nanoformulations, including liposomes, micelles, polymeric vesicles, micro/nanoemulsions, polymeric nanoparticles, and hydrogel nanoparticles, have shown improved solubility, enhanced tumor cytotoxicity, prolonged drug release, and reduced side effects.
Doxorubicin (DOX) is a natural antibiotic with antineoplastic activity. It has been used for over 40 years and remains one of the most used drugs in chemotherapy for a variety of cancers. However, cardiotoxicity limits its use for long periods. To overcome this limitation, encapsulation in smart drug delivery systems (DDS) brings advantages in comparison with free drug administration (i.e., conventional anticancer drug therapy). In this review, we present the most relevant nanostructures used for DOX encapsulation over the last 10 years, such as liposomes, micelles and polymeric vesicles (i.e., polymersomes), micro/nanoemulsions, different types of polymeric nanoparticles and hydrogel nanoparticles, as well as novel approaches for DOX encapsulation. The studies highlighted here show these nanoformulations achieved higher solubility, improved tumor cytotoxicity, prolonged DOX release, as well as reduced side effects, among other interesting advantages.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据